Nuvectis Pharma, Inc.
NVCTHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Nuvectis Pharma, Inc. focuses on Biotechnology services and products. Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The $783.1M market capitalization puts NVCT squarely in small-cap range for its industry. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Market Cap
$783.1M
Beta
-0.26
P/E (TTM)
—
P/E (Fwd)
-24.99
EPS (TTM)
$-1.32
EPS (Fwd)
$-0.96
ROE
-214.6%
ROA
-73.1%
Cash
$22.2M
Total Debt
$0
Free CF
-$8.9M
52W Change
290.0%
Annual Financials
Cash vs Debt
Where NVCT stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, NVCT finished 82.82% above its 150-day moving average ($12.98) and 105.28% above its 200-day moving average ($11.56). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NVCT overbought or oversold?
At the August 31, 2026 close, NVCT's RSI(14) was 72.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Nuvectis Pharma, Inc. reports $22.2M in cash and $0 in total debt. Free cash flow is running at -$8.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -214.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Nuvectis Pharma, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Nuvectis Pharma, Inc.'s trajectory.